Dr Patrick Hwu is Head Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, additionally he is President Elect to the Society for Immunotherapy of Cancer (SITC), 2019-2024. He is a tumor immunologist focused on the areas of vaccines, adoptive T-cell therapies, and immunotherapy resistance. His research and clinical efforts have led to insights and advances in the understanding of the interactions between tumors and the immune system, and the development of cellular therapies. Ongoing clinical trials are being conducted based on his group’s work, including a trial of T-cells gene-modified to enhance resistance against TGF-. Most recently, his preclinical studies have focused on combinations of immune checkpoint blockade and T-cell therapy, as well as rational combinations of targeted therapies and immunotherapies.